{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo%2C+Cohort+3&page=22",
    "query": {
      "intervention": "Placebo, Cohort 3",
      "page": 22
    },
    "page_size": 10
  },
  "pagination": {
    "page": 22,
    "page_size": 10,
    "total_count": 1069,
    "total_pages": 107,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo%2C+Cohort+3&page=23&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo%2C+Cohort+3&page=21&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-16T10:16:19.678Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04327765",
      "title": "Staccato® Granisetron Multiple Dose PK",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "0.5mg AZ-010",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "1mg AZ-010",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "3mg AZ-010",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Alexza Pharmaceuticals, Inc.",
      "sponsor_class": "UNKNOWN",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 30,
      "start_date": "2020-03-10",
      "completion_date": "2020-08-15",
      "has_results": false,
      "last_update_posted_date": "2020-10-30",
      "last_synced_at": "2026-10-16T10:16:19.678Z",
      "location_count": 1,
      "location_summary": "Tempe, Arizona",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04327765"
    },
    {
      "nct_id": "NCT01663857",
      "title": "A Study LY2228820 for Recurrent Ovarian Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Epithelial Ovarian Cancer",
        "Fallopian Tube Cancer",
        "Primary Peritoneal Cancer"
      ],
      "interventions": [
        {
          "name": "LY2228820",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 118,
      "start_date": "2012-07",
      "completion_date": "2018-05-11",
      "has_results": true,
      "last_update_posted_date": "2019-09-11",
      "last_synced_at": "2026-10-16T10:16:19.678Z",
      "location_count": 19,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Sarasota, Florida + 15 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01663857"
    },
    {
      "nct_id": "NCT06693843",
      "title": "A Phase 2b, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Obesity, Overweight, or Chronic Weight Management"
      ],
      "interventions": [
        {
          "name": "Aleniglipron or Placebo",
          "type": "DRUG"
        },
        {
          "name": "Aleniglipron",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "79 Years",
        "sex": "ALL",
        "summary": "18 Years to 79 Years"
      },
      "enrollment_count": 230,
      "start_date": "2024-10-28",
      "completion_date": "2026-07-09",
      "has_results": false,
      "last_update_posted_date": "2026-08-10",
      "last_synced_at": "2026-10-16T10:16:19.678Z",
      "location_count": 39,
      "location_summary": "Phoenix, Arizona • Anaheim, California • Los Angeles, California + 33 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Montclair",
          "state": "California"
        },
        {
          "city": "Rancho Cucamonga",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06693843"
    },
    {
      "nct_id": "NCT07558668",
      "title": "A 3-part Study of SYX-5219 in Healthy Volunteers and Participants With Atopic Dermatitis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Moderate to Severe Atopic Dermatitis"
      ],
      "interventions": [
        {
          "name": "SYX-5219 Oral Capsule",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sitryx Therapeutics Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 149,
      "start_date": "2025-02-26",
      "completion_date": "2026-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-04-30",
      "last_synced_at": "2026-10-16T10:16:19.678Z",
      "location_count": 6,
      "location_summary": "Arkansas City, Arkansas • Fremont, California • Plainfield, Indiana + 3 more",
      "locations": [
        {
          "city": "Arkansas City",
          "state": "Arkansas"
        },
        {
          "city": "Fremont",
          "state": "California"
        },
        {
          "city": "Plainfield",
          "state": "Indiana"
        },
        {
          "city": "Boardman",
          "state": "Ohio"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07558668"
    },
    {
      "nct_id": "NCT02106897",
      "title": "Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Single Doses and Multiple Doses of BIIB059 (Litifilimab) in Healthy Volunteers and Participants With Systemic Lupus Erythematosus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Systemic Lupus Erythematosus",
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "BIIB059 (litifilimab)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 109,
      "start_date": "2014-04-30",
      "completion_date": "2016-05-24",
      "has_results": false,
      "last_update_posted_date": "2023-01-31",
      "last_synced_at": "2026-10-16T10:16:19.678Z",
      "location_count": 5,
      "location_summary": "Anniston, Alabama • Birmingham, Alabama • Orlando, Florida + 2 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Great Neck",
          "state": "New York"
        },
        {
          "city": "Duncansville",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02106897"
    },
    {
      "nct_id": "NCT05353985",
      "title": "A Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attempting a Gluten-Free Diet",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Celiac Disease"
      ],
      "interventions": [
        {
          "name": "TAK-062",
          "type": "DRUG"
        },
        {
          "name": "Simulated Inadvertent Gluten Exposure (SIGE) Gluten-Bar",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "TAK-062 Placebo",
          "type": "DRUG"
        },
        {
          "name": "Simulated Inadvertent Gluten Exposure (SIGE) Gluten-free Bar",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 153,
      "start_date": "2022-06-30",
      "completion_date": "2024-11-06",
      "has_results": true,
      "last_update_posted_date": "2025-08-20",
      "last_synced_at": "2026-10-16T10:16:19.678Z",
      "location_count": 61,
      "location_summary": "Birmingham, Alabama • Litchfield Park, Arizona • Paradise Valley, Arizona + 52 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Litchfield Park",
          "state": "Arizona"
        },
        {
          "city": "Paradise Valley",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05353985"
    },
    {
      "nct_id": "NCT06873035",
      "title": "An Interventional Study of Infigratinib in Children With Hypochondroplasia",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Hypochondroplasia"
      ],
      "interventions": [
        {
          "name": "infigratinib 0.128 mg/kg/day",
          "type": "DRUG"
        },
        {
          "name": "infigratinib 0.25 mg/kg/day",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "QED Therapeutics, a BridgeBio company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "3 Years to 18 Years"
      },
      "enrollment_count": 24,
      "start_date": "2025-04-22",
      "completion_date": "2027-01",
      "has_results": false,
      "last_update_posted_date": "2026-07-16",
      "last_synced_at": "2026-10-16T10:16:19.678Z",
      "location_count": 8,
      "location_summary": "Oakland, California • Aurora, Colorado • Washington D.C., District of Columbia + 5 more",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Columbia",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06873035"
    },
    {
      "nct_id": "NCT01105598",
      "title": "A Multiple Ascending Dose Study of ETC-1002 in Subjects With Mild Dyslipidemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Mild Dyslipidemia"
      ],
      "interventions": [
        {
          "name": "ETC-1002 or placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Esperion Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 53,
      "start_date": "2010-04-20",
      "completion_date": "2010-10-02",
      "has_results": false,
      "last_update_posted_date": "2019-03-28",
      "last_synced_at": "2026-10-16T10:16:19.678Z",
      "location_count": 1,
      "location_summary": "Kalamazoo, Michigan",
      "locations": [
        {
          "city": "Kalamazoo",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01105598"
    },
    {
      "nct_id": "NCT04325802",
      "title": "Treatment of Chronic Itch in Atopic Dermatitis With Opioid Antagonist Naltrexone",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Atopic Dermatitis",
        "Pruritus",
        "Pruritus Chronic",
        "Dermatitis"
      ],
      "interventions": [
        {
          "name": "Naltrexone",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 0,
      "start_date": "2022-12-31",
      "completion_date": "2024-06",
      "has_results": false,
      "last_update_posted_date": "2023-04-04",
      "last_synced_at": "2026-10-16T10:16:19.678Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04325802"
    },
    {
      "nct_id": "NCT05698095",
      "title": "Pharmacokinetics, Safety, and Tolerability of Intramuscular 5-MeO-DMT in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pharmacokinetics",
        "Safety",
        "Tolerability"
      ],
      "interventions": [
        {
          "name": "5-methoxy-N,N-dimethyltryptamine succinate salt",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Usona Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 54,
      "start_date": "2022-12-27",
      "completion_date": "2023-09-07",
      "has_results": false,
      "last_update_posted_date": "2023-11-30",
      "last_synced_at": "2026-10-16T10:16:19.678Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05698095"
    }
  ]
}